Press release
Mitochondrial Diseases (Metabolic Disorders) Market 2021 Industry Analysis by Manufacturers – Abliva AB, Astellas Pharma Inc, Demuris Ltd, Energenesis Biomedical Co Ltd
The Mitochondrial Diseases (Metabolic Disorders) Market report offers an in-depth assessment of market dynamics, the competitive landscape, segments, and regions in order to help readers to become familiar with the Mitochondrial Diseases (Metabolic Disorders) market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to plan effective strategies for gaining successful in the Mitochondrial Diseases (Metabolic Disorders) market. Importantly, it allows players to gain deep insights into the business development and market growth of leading companies operating in the Mitochondrial Diseases (Metabolic Disorders) market.Get a Free Sample Copy of This Report:
https://www.marketinsightsreports.com/reports/11023648925/mitochondrial-diseases-metabolic-disorders-drugs-in-development-2021/inquiry?Mode=namita
Top Leading Companies of Mitochondrial Diseases (Metabolic Disorders) Market are - Abliva AB, Astellas Pharma Inc, Demuris Ltd, Energenesis Biomedical Co Ltd, Generian Pharmaceuticals Inc, Khondrion BV, Mission Therapeutics Ltd, Mitobridge Inc, OMEICOS Therapeutics GmbH, PTC Therapeutics Inc, SBI Pharmaceuticals Co Ltd, Triplex Therapeutics Inc, Yungjin Pharm Co Ltd and others.
Industry News and Updates:
April 29, 2019: OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation
BERLIN--OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the dosing of a first patient in a Phase 2 clinical study for the company’s OMT-28 development program. The placebo-controlled, double-blind, randomized PROMISE-AF study will evaluate the efficacy, safety, and population pharmacokinetics in patients with persistent Atrial Fibrillation (AF). The study is expected to enroll up to 120 patients via centers in four European countries. The completion of the PROMISE-AF trial is expected for H1 2020 and should enable OMEICOS to transition OMT-28 into Phase III clinical evaluation.
Market Overview:
Mitochondrial diseases are characterized by chronic, genetic and progressive medical symptoms that arise due to inherited or spontaneous mutations in mitochondrial DNA (a small, circular, double-stranded with ~16,500 base pairs that exists outside of the nucleus), or in some cases, nuclear DNA, which adversely alter the function of mitochondria. Such clinical conditions are rare and are known to affect multiple parts of the body, including neurons and nerves, kidneys, heart, liver, eyes, ears, and pancreas. It is worth highlighting that over 300 mutations have been identified and are associated with various mitochondrial diseases. Examples of diseases that are caused due to mutations in mitochondrial DNA include Leber's hereditary optic neuropathy (LHON), Leigh syndrome, mitochondrial DNA depletion syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), and myoclonic epilepsy with ragged red fibers (MERRF).
Investigator Observers Strong Growth in Specific Regions:
– Europe Market (Germany, UK, France, Russia, Italy)
– Center East and Africa Market (Saudi Arabia, UAE, Egypt, Nigeria, South Africa)
– South America Market (Brazil, Argentina, Colombia)
– North America Market (United States, Canada, Mexico)
– Asia Pacific Market (China, Japan, Korea, India, Southeast Asia).
Scope of Mitochondrial Diseases (Metabolic Disorders) Market Report:
- The report provides a snapshot of the global therapeutic landscape of Mitochondrial Diseases (Metabolic Disorders).
- The report reviews product therapeutics for Mitochondrial Diseases (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers the products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The report features descriptive drug profiles for the products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The report reviews key companies involved in Mitochondrial Diseases (Metabolic Disorders) maket therapeutics and enlists all their major and minor projects.
- The report evaluates Mitochondrial Diseases (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The report encapsulates all the dormant and discontinued pipeline projects.
- The report reviews latest news related to the product therapeutics for Mitochondrial Diseases (Metabolic Disorders)
Browse Full Report at:
https://www.marketinsightsreports.com/reports/11023648925/mitochondrial-diseases-metabolic-disorders-drugs-in-development-2021?Mode=namita
Reasons to Buy This Report:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mitochondrial Diseases (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for market projects by understanding Mitochondrial Diseases (Metabolic Disorders) depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from market.
We Offer Customization on Report Based on Specific Client Requirement:
- Country Level analysis for any 5 countries of your choice.
- Competitive analysis of any 5 key market players.
- 40 analyst hours to cover any other data point.
Contact Us:
Irfan Tamboli (Head of Sales) – Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com
About Us:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mitochondrial Diseases (Metabolic Disorders) Market 2021 Industry Analysis by Manufacturers – Abliva AB, Astellas Pharma Inc, Demuris Ltd, Energenesis Biomedical Co Ltd here
News-ID: 2454210 • Views: …
More Releases from Market Insights Reports
Cold Chain Monitoring Market May See a Big Move | BlueAir, Denso, Eureka Forbes, …
Market Insights Reports published a new research publication on "Cold Chain Monitoring Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Cold Chain Monitoring market was mainly driven by the increasing R&D spending across the world.
Some of the key players…
Outbound Logistics Market Next Big Thing | Major Giants- Draexlmaier, Faurecia, …
Market Insights Reports published a new research publication on "Outbound Logistics Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Outbound Logistics market was mainly driven by the increasing R&D spending across the world.
Some of the key players profiled in…
Veterinary Telemedicine Market May See a Big Move | Nestle, Deuerer, The J.M. Sm …
Market Insights Reports published a new research publication on "Veterinary Telemedicine Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Veterinary Telemedicine market was mainly driven by the increasing R&D spending across the world.
Some of the key players profiled in…
Precision Planting Market is Set to Fly High in Years to Come
Market Insights Reports published a new research publication on "Precision Planting Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Precision Planting market was mainly driven by the increasing R&D spending across the world.
Some of the key players profiled in…
More Releases for Mitochondrial
Mitochondrial Myopathies Market Trends,Developments, and Growth Opportunities
Mitochondrial myopathies are a group of rare, genetically inherited neuromuscular disorders that result from dysfunction in the mitochondria-the powerhouses of the cell. These conditions often manifest as muscle weakness, fatigue, exercise intolerance, and in severe cases, multi-system complications affecting the heart, brain, and other organs. With increasing recognition of rare diseases, advancements in genetic diagnostics, and novel therapeutic development, the Mitochondrial Myopathies market is experiencing significant growth potential.
Download Full PDF…
Primary Mitochondrial Myopathies Pipeline Insight 2025: Novel Mitochondrial Modu …
The therapeutic landscape for Primary Mitochondrial Myopathies (PMM) is evolving rapidly, with novel approaches emerging to address the debilitating effects of impaired mitochondrial energy metabolism. PMM, a rare and heterogeneous group of disorders, currently lacks disease-modifying treatments, with care largely limited to symptom management, supportive measures, and nutritional supplements. This ongoing unmet need is fueling innovation across multiple therapeutic modalities.
DelveInsight's "Primary Mitochondrial Myopathies - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/primary-mitochondrial-myopathies-pmm-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" highlights an…
Brain Recovery After Concussion: Neurofeedback & Hyperbaric Oxygen for Mitochond …
San Diego, CA - August 06, 2025 - An increasing amount of neuroscience research shows that the real damage of a concussion goes far beyond just a "bump on the head." At the cellular level, concussions can cause mitochondrial problems, leading to a chain reaction of metabolic, inflammatory, and cognitive issues in the brain. New therapies like neurofeedback and hyperbaric oxygen therapy (HBOT) are now demonstrating promising results in helping…
Mitochondrial Complex Activity Assay Kits Market Growth by 2034
The global mitochondrial complex activity assay kits market is poised for a major leap, projected to reach USD 567 million by 2034 from an estimated USD 275 million in 2024, growing at a CAGR of 7.4%. This growth is fueled by increased demand for mitochondrial health assessment in drug discovery, cancer research, and chronic disease diagnostics.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/67131
Key Highlights:
• Market Size (2024): USD 275 million
• Forecasted…
Advanced Mitochondrial Formula Reviews: The Real Fact About Advanced Mitochondri …
Advanced Mitochondrial Formula Reviews: The Real Fact About Advanced Mitochondrial Formula
It started with small things. Skipping your morning jog because you "didn't sleep well." Grabbing an extra cup of coffee by mid-afternoon just to make it through another Zoom meeting. Forgetting simple names or misplacing your phone more often. Maybe you've brushed it off as stress, getting older, or just the pace of modern life but deep down, you know…
Primary Mitochondrial Myopathies (PMM) Pipeline: Advancing Therapies Targeting M …
The therapeutic landscape for Primary Mitochondrial Myopathies (PMM) is rapidly progressing, driven by the urgent need to address the complex and heterogeneous nature of these rare genetic disorders characterized by mitochondrial dysfunction and impaired energy production. Despite limited approved treatment options, ongoing research focuses on novel approaches to improve mitochondrial function, enhance cellular energy metabolism, and alleviate symptoms. Leading biotech and pharmaceutical companies, including Stealth BioTherapeutics, Omeicos Therapeutics GmbH, and…
